<DOC>
	<DOCNO>NCT02000934</DOCNO>
	<brief_summary>This study open-label , multicenter , phase 1 , dose escalation study TAK-659 adult patient advance solid tumor lymphoma malignancy . This study first administer TAK-659 human . The patient population dose escalation ( Part A ) consist adult previously diagnose form solid tumor lymphoma standard , curative , life-prolonging treatment exist longer effective . This first-in-human ( FIH ) study include 5 dose expansion cohort refractory and/or relapse Chronic Lymphocytic Leukemia ( CLL ) , Diffuse Large B Cell Lymphoma ( DLBCL ) , indolent Non Hodgkin Lymphoma ( iNHL ) , Mantle Cell Lymphoma ( MCL ) , Post Transplant Lymphoproliferative Disorder ( PTLD ) ( Part B ) follow completion dose escalation ( Part A ) .</brief_summary>
	<brief_title>A Study TAK-659 Adult Patients With Advanced Solid Tumor Lymphoma Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Each patient must meet follow inclusion criterion enrol study : 1 . Male female patient 18 year old 2 . To enrol dose escalation ( Part A ) , patient must 1. histologically cytologically confirm diagnosis metastatic and/or advance solid tumor malignancy lymphoma , effective standard treatment available . However , patient primary brain tumor WM exclude . 2 . Radiographically clinically measurable nonmeasurable ( evaluable ) disease . Radiographically measurable disease determine RECIST ( version 1.1 ) solid tumor IWG criterion malignant lymphoma ( 2007 IWG ) . 3 . To enrol dose expansion cohort ( Part B ) , patient must meet following criterion : 1 . Histologically confirm diagnosis CLL meet IWCLL 2008 criterion Cohort 1 ; DLBCL Cohort 2 ; Bcell NHL ( FL [ Grade 1 , 2 , 3a ] , SLL , LPL/WM , MZL [ splenic , nodal , extranodal ] ) Cohort 3 ; MCL Cohort 4 ; PTLD ( early lesion , polymorphic , monomorphic , classical Hodgkin lymphomatype , EBVpositive DLBCL elderly , DLBCL associate chronic inflammation ; along document documentable EBER status tissue ISH ) Cohort 5 2 . Must receive ≥ 1 prior therapy ( exclude radiation ) ; either treatment naïve , relapsed/refractory , treatment failure due reason ibrutinib , idelalisib , investigational BCR pathway inhibitor directly target SYK ; consider appropriate treatment retreatment purine analogbased therapy ( CLL ) ; consider ineligible least 1 prior therapy ( PTLD ) 3 . Radiographically clinically measurable and/or evaluable disease specify protocol 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Patients must adequate organ function , include bone marrow reserve , hepatic , renal function describe protocol 6 . Female patient postmenopausal least 1 year , surgically sterile , childbearing potential agree use 2 effective method ( ) contraception study treatment period 6 month last dose study drug practice true abstinence . Male patient , even surgically sterilize , agree practice effective barrier contraception study treatment period 6 month last dose study drug practice true abstinence . 7 . Voluntary write consent must give performance study relate procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . 8 . Patients must recover reversible effect prior anticancer therapy ( Grade ≤ 1 ) . Exclusion Criteria Patients meeting follow exclusion criterion enrol study . 1 . Patients brain metastasis , patient active secondary malignancy require treatment , exception describe protocol 2 . Any serious medical psychiatric illness , include drug alcohol abuse , could , investigator 's opinion , potentially interfere completion treatment accord protocol . 3 . Lifethreatening illness unrelated cancer ; major surgery , systemic infection require intravenous ( IV ) antibiotic therapy serious infection within 14 day first dose study drug . 4 . Female patient pregnant lactate . 5 . Any immunotherapy , chemotherapy , radiotherapy , investigational therapy within 24 week first dose study treatment , detail protocol 6 . For escalation cohort expansion cohort exclude PTLD , autologous stem cell transplant within 6 month Day 1 Cycle 1 , prior allogeneic stem cell transplant time . 7 . Treatment high dose corticosteroid ( &gt; daily dose equivalent 10 mg oral prednisone ) anticancer purpose within 7 day first dose TAK659 . 8 . Known human immunodeficiency virus ( HIV ) positive ; know hepatitis B surface antigenpositive ; know suspect active hepatitis C infection ( test require ) . 9 . Evidence currently uncontrolled cardiovascular condition list protocol . 10 . Known GI disease GI procedure could interfere oral absorption tolerance TAK659 include difficulty swallow tablet ; diarrhea &gt; Grade 1 despite supportive therapy . 11 . Lack suitable venous access require blood sample 12 . Use consumption Pgp inducers/inhibitors strong CYP3A inducers/inhibitors describe protocol , grapefruitcontaining food beverage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TAK-659</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>CLL</keyword>
	<keyword>DLBCL</keyword>
</DOC>